Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Phase 2
60
about 8.3 years
18+
Male only
1 site in MD
What this study is about
Researchers are testing whether giving testosterone (a treatment) along with darolutamide can help men with advanced prostate cancer live longer. The trial will also look at how this treatment affects their quality of life, gene expression, and metabolism.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Darolutamide
- 2.Take Luteinizing hormone-releasing hormone (LHRH) analogue
- 3.Take Testosterone cypionate
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
darolutamide, gonadorelin, Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) (Androgen Receptor Agonists)
oral (Oral Tablet), injection, intramuscular
Primary: Percent of subjects free of Clinical or radiographic free progression
Secondary: Number of patients with Clinical or Radiographic progression free survival, Objective Response to darolutamide, Overall Survival
Oncology